Edit
Trince Bio
http://www.trincebio.com/Last activity: 08.08.2024
Active - Reference to LumiPore Tranfection Technology
Trince is dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company’s LumiPore transfection platform, which is covered by a portfolio of pending patents, is used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology ensures that this is done in a gentle manner, maximizing the therapeutic quality of the final cell product. www.trincebio.com
Location: Belgium, East Flanders, Ghent
Employees: 1-10
Total raised: $4.53M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Novalis Bi... | noval.is |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.12.2021 | - | $4.53M | Qbic Fund |
Mentions in press and media 4
| Date | Title | Description |
| 08.08.2024 | Novalis II portfolio company Trince awarded winner of Nature Spinoff Prize 2024 | July 11th 2024, Ghent (BE). Novalis II portfolio company Trince is awarded the Spinoff Prize from the prestigious Nature Magazine |
| 19.03.2024 | European Innovation Council Awards €2.5 M Grant to Trince, NecstGen, and IBSAL for Advancing Cell Therapy Manufacturing | GHENT, BELGIUM, March 19, 2024 /EINPresswire.com/ -- Following a rigorous selection process by an expert panel, Trince, NecstGen, and IBSAL are proud to announce that their “Penphomet” project has been selected by The European Innovation Co... |
| 23.12.2021 | Trince raises ⬠4M with support of Qbic II | Ghent, Belgium, 4 December 2021 – Trince, a spin-off of Ghent University (UGent), is developing innovative and efficient technology to insert genetic material into cells. This genetic modification of cells is essential in, for example, cell... |
| 06.12.2021 | Trince Raises €4M in Funding | Trince, a spin-off of Ghent University (UGent) developing innovative and efficient technology to insert genetic material into cells, raised €4m in funding. Backers included Novalis Biotech Acceleration, Qbic II, and private investors. The c... |